AGEN Agenus Inc. - Fundamental Analysis
BEARISH
Sign in to save
Save this symbol to a watchlist or track a position.
AGEN Stock | Fundamental Analysis & Investment Insights
NASDAQ
Healthcare
Biotechnology
Current Price
Live
$3.24
Analyst Target
$12.33
+280.7%
Upside
52W High
$7.34
52W Low
$1.38
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Jan 24, 2026
Market cap
$117.1M
P/E
N/A
ROE
N/A
Profit margin
-32.9%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
Powered by advanced machine learning algorithms
Confidence Score
85%
Analysis Accuracy
The Advanced Deterministic Scorecard reveals critical weaknesses: a Piotroski F-Score of 0/9 indicates severe financial distress, and the absence of an Altman Z-Score due to negative book value raises serious solvency concerns. Despite a 20.4% YoY revenue growth and a bullish analyst target price of $12.33, the company is deeply unprofitable with negative margins across all metrics, deteriorating cash position, and alarming liquidity ratios (Current Ratio: 0.47, Quick Ratio: 0.03). Persistent earnings misses, a -95.8% 5-year price decline, and lack of insider buying further undermine confidence. The stock appears highly speculative with substantial fundamental risks outweighing growth potential.
Key Strengths
20.4% Year-over-Year Revenue Growth indicates commercial or partnership traction
Analyst consensus recommendation is 'buy' with a high target price of $12.33
Forward P/E of 1.66 suggests extremely low valuation relative to future earnings expectations
Price/Sales of 1.10 is moderate for a biotech firm with growth potential
Recent quarters show narrowing losses compared to prior deep negative EPS
Key Risks
Piotroski F-Score of 0/9 signals extreme financial weakness and high risk of operational failure
Negative Price/Book (-0.39) and lack of Altman Z-Score indicate potential insolvency and balance sheet distress
Critically low liquidity: Current Ratio of 0.47 and Quick Ratio of 0.03 suggest imminent cash flow crisis
Consistently negative profitability: ROA of -16.66%, Gross Margin of 0.08%, and -32.92% Profit Margin
Earnings volatility with 3 of last 4 quarters missing estimates by over -50%, including -152.9% and -173.9% surprises
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
25
Weak
45
52
20
10
0
AI Verdict
High-risk speculative position with unsustainable financial health
Key drivers: Piotroski F-Score of 0, Negative book value and undefined Altman Z-Score, Extremely weak liquidity metrics, Persistent earnings misses and negative cash flow, Analyst optimism not yet supported by fundamentals
Confidence
88%
Value
45/100
Ref P/E, PEG, Graham Number
Positives
- Low Forward P/E of 1.66 implies high future earnings expectations
- Price/Sales of 1.10 is below sector average of 62.63% growth peers
Watchpoints
- Price/Book is negative (-0.39), invalidating traditional value metrics
- No Graham Number due to unprofitability
- P/E and PEG ratios are undefined, limiting value assessment
Future
52/100
Ref Growth rates
Positives
- 20.4% YoY Revenue Growth shows potential commercial momentum
- Forward P/E implies strong earnings improvement expected
- Analyst target price implies 279% upside, signaling high growth expectations
Watchpoints
- No Q/Q earnings growth data available
- Earnings Growth YoY is undefined, indicating no profitability baseline
- Historical earnings progression shows erratic and negative trends
Past
20/100
Ref Historical trends
Positives
- Some quarters show improved EPS versus prior deep losses (e.g., 2025-05-12 vs 2023-08-08)
Watchpoints
- 5-year price return of -95.8% reflects severe investor erosion
- 3-year return of -93.6% and 6-month return of -45.6% show persistent underperformance
- 21 of last 25 quarters had negative EPS
- Average earnings surprise over last 4 quarters is -92.94%
Health
10/100
Ref Altman Z-Score, Piotroski F-Score
Positives
No standout positives identified.
Watchpoints
- Piotroski F-Score of 0/9 indicates critical financial weakness
- Current Ratio of 0.47 and Quick Ratio of 0.03 signal near-term liquidity crisis
- Negative book value and undefined ROE/ROIC point to balance sheet insolvency
- No Altman Z-Score due to financial distress
Dividend
0/100
Ref Yield, Payout
Positives
No standout positives identified.
Watchpoints
- Dividend Strength of 0/100
- No dividend yield or payout history
- Payout Ratio is 0.00% due to lack of earnings
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$3.24
Analyst Target
$12.33
Upside/Downside
+280.7%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for AGEN and closest competitors.
Updated 2026-01-23
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
AGEN
Agenus Inc.
Primary
|
-95.8% | -93.6% | -13.8% | -45.6% | -3.3% | -3.0% |
|
ANL
Adlai Nortye Ltd.
Peer
|
-82.5% | -82.5% | +28.3% | +82.6% | +71.9% | +46.1% |
|
BDSX
Biodesix, Inc.
Peer
|
-97.8% | -75.2% | -34.9% | +31.6% | +72.1% | +49.0% |
|
ANIK
Anika Therapeutics, Inc.
Peer
|
-72.8% | -67.0% | -41.2% | +29.0% | +6.3% | +13.3% |
|
ADAG
Adagene Inc.
Peer
|
-87.3% | +73.8% | +79.6% | +92.3% | +80.6% | +23.6% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
N/A
Forward P/E
1.66
PEG Ratio
N/A
P/B Ratio
-0.39
P/S Ratio
1.1
EV/Revenue
1.37
EV/EBITDA
-2.91
Market Cap
$117.1M
Profitability
Profit margins and return metrics
Profit Margin
-32.92%
Operating Margin
-16.08%
Gross Margin
0.08%
ROE
N/A
ROA
-16.66%
Growth
Revenue and earnings growth rates
Revenue Growth
+20.4%
Earnings Growth
N/A
Q/Q Revenue Growth
N/A
Q/Q Earnings Growth
N/A
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
0.47
Weak
Quick Ratio
0.03
Poor
Cash/Share
$0.1
Quarterly Earnings History
EPS performance vs analyst estimates
2026-03-10
$N/A
2025-11-10
$-1.16
-152.9% surprise
2025-08-11
$-1.0
-173.9% surprise
2025-05-12
$-1.03
+48.0% surprise
Healthcare Sector Comparison
Comparing AGEN against 146 companies in the Healthcare sector
(10 bullish, 60 neutral, 76 bearish)
Profit Margin
-32.92%
This Stock
vs
-20.8%
Sector Avg
+58.3%
(Superior)
Revenue Growth
20.4%
This Stock
vs
61.93%
Sector Avg
-67.1%
(Slower)
Current Ratio
0.47
This Stock
vs
3.47
Sector Avg
-86.5%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
AGEN
Agenus Inc.
|
BEARISH | $117.1M | - | -% | -32.9% | $3.24 | |
|
ANL
Adlai Nortye Ltd.
|
BEARISH | $97.05M | - | -139.0% | -% | $2.63 | |
|
BDSX
Biodesix, Inc.
|
BEARISH | $93.92M | - | -302.6% | -49.3% | $11.74 | |
|
ANIK
Anika Therapeutics, Inc.
|
BEARISH | $150.85M | - | -8.7% | -29.3% | $10.46 | |
|
ADAG
Adagene Inc.
|
BULLISH | $153.18M | - | -63.3% | -% | $3.25 |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-01-09 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,780 | $14,780 |
| 2026-01-02 | HARRISON THOMAS L | Director | Stock Award | 7,691 | $24,842 |
| 2025-12-26 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,942 | $16,358 |
| 2025-12-12 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,316 | $16,358 |
| 2025-11-28 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,587 | $16,357 |
| 2025-11-14 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,769 | $16,357 |
| 2025-10-31 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,120 | $16,356 |
| 2025-10-17 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 4,216 | $16,358 |
| 2025-10-03 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,951 | $16,357 |
| 2025-10-01 | HARRISON THOMAS L | Director | Stock Award | 5,780 | $22,542 |
| 2025-09-19 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,734 | $16,355 |
| 2025-09-05 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,778 | $16,359 |
| 2025-08-22 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,619 | $16,358 |
| 2025-08-08 | ARMEN GARO H. | Chief Executive Officer | Stock Award | 3,407 | $16,354 |
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
BUY
3 analysts
HC Wainwright & Co.
2025-09-10
Buy
Buy
HC Wainwright & Co.
2025-08-28
Buy
Buy
Past News Coverage
Recent headlines mentioning AGEN from our newsroom.
Newest → oldest
No matching news yet.